Table 2 Efficacy and safety of different drugs according to pairwise estimates.

From: Comparative efficacy and safety of urate-lowering therapy for the treatment of hyperuricemia: a systematic review and network meta-analysis

Intervention Pairwise meta-analysis odds ratio (and 95% CI) No. of participants No. of trials No. of events Heterogeneity I2 (variation in OR attributable to heterogeneity)
Efficacy
allopurinol vs.
 Benzbromarone 2.28 (0.21, 24.64) 92 2 29 73.7%
 febuxostat 40 mg QD 1.29 (1.05, 1.59) 2442 5 1364 14.2%
 febuxostat 60 mg QD 8.13 (0.39, 167.90) 24 1 5 NA
 febuxostat 80 mg QD 3.62 (2.69, 4.89) 3287 6 100 69.3%
 febuxostat 120 mg QD 6.34 (4.79, 8.40) 1012 2 420 0.0%
 febuxostat 240 mg QD 18.31 (9.17, 36.58) 389 1 171 NA
 Placebo 0.01 (0.00, 0.09) 390 1 287 NA
benzbromarone vs.
 Probenecid 0.63 (0.05, 7.39) 55 1 3 NA
febuxostat 20 mg QD vs.
 febuxostat 40 mg QD 7.39 (3.29, 16.63) 153 2 52 0.0%
 febuxostat 60 mg QD 5.75 (1.99, 16.63) 79 1 29 NA
 febuxostat 80 mg QD 8.28 (2.73, 25.15) 84 1 28 NA
 Placebo 0.03 (0.00, 0.14) 149 2 112 0.0%
febuxostat 40 mg QD vs.
 febuxostat 60 mg QD 1.16 (0.38, 3.58) 94 2 14 0.0%
 febuxostat 80 mg QD 2.28 (1.92, 2.70) 2328 5 1073 0.0%
 febuxostat 120 mg QD 12.63 (2.60, 61.38) 68 1 17 NA
 Placebo 0.00 (0.00, 0.02) 215 3 130 0.0%
febuxostat 60 mg QD vs.
 febuxostat 80 mg QD 1.44 (0.40, 5.19) 77 1 11 NA
 Placebo 0.01 (0.00, 0.05) 74 1 43 NA
febuxostat 80 mg QD vs.
 febuxostat 120 mg QD 1.48 (1.05, 2.08) 1080 3 250 18.6%
 febuxostat 240 mg QD 4.44 (2.20, 8.96) 379 1 80 NA
 Placebo 0.00 (0.00, 0.01) 531 3 282 0.0%
febuxostat 120 mg QD vs.
 febuxostat 240 mg QD 3.11 (1.53, 6.32) 371 1 66 NA
 Placebo 0.00 (0.00, 0.01) 461 2 219 0.0%
febuxostat 240 mg QD vs.
 Placebo 0.00 (0.00, 0.01) 253 1 136 NA
pegloticase 8 mg 2 W vs.
 pegloticase 8 mg 4 W 1.39 (0.75, 2.60) 169 1 104 NA
 Placebo 0.02 (0.00, 0.36) 127 1 98 NA
pegloticase 8 mg 4 W vs.
 Placebo 0.02 (0.00, 0.26) 128 1 92 NA
Safety
allopurinol vs.
 Benzbromarone 0.29 (0.05, 1.62) 55 1 7 NA
 febuxostat 40 mg QD 0.99 (0.84, 1.16) 2436 4 1345 0.0%
 febuxostat 80 mg QD 1.17 (0.99, 1.38) 3345 6 2024 12.3%
 febuxostat 120 mg QD 1.56 (1.17, 2.08) 1040 2 787 0.0%
 febuxostat 240 mg QD 1.08 (0.67, 1.73) 402 1 298 NA
 Placebo 1.12 (0.70, 1.79) 402 1 297 NA
benzbromarone vs.
 Probenecid 0.42 (0.12, 1.41) 55 1 17 NA
febuxostat 20 mg QD vs.
 febuxostat 40 mg QD 1.27 (0.64, 2.51) 153 2 102 0.0%
 febuxostat 60 mg QD 0.84 (0.33, 2.14) 79 1 51 NA
 febuxostat 80 mg QD 1.08 (0.45, 2.61) 84 1 52 NA
 Placebo 1.10 (0.54, 2.22) 149 2 102 0.0%
febuxostat 40 mg QD vs.
 febuxostat 60 mg QD 0.78 (0.31, 1.99) 77 1 49 NA
 febuxostat 80 mg QD 1.09 (0.93, 1.29) 2352 5 1241 0.0%
 febuxostat 120 mg QD 1.18 (0.48, 2.91) 75 1 39 NA
 Placebo 0.96 (0.56, 1.68) 221 3 135 0.0%
febuxostat 60 mg QD vs.
 febuxostat 80 mg QD 1.28 (0.50, 3.26) 77 1 49 NA
 placebo 1.45 (0.56, 3.75) 74 1 46 NA
febuxostat 80 mg QD vs.
 febuxostat 120 mg QD 1.14 (0.87, 1.48) 1121 3 800 0.0%
 febuxostat 240 mg QD 0.77 (0.49, 1.22) 401 1 279 NA
 placebo 0.93 (0.64, 1.35) 558 3 367 0.0%
febuxostat 120 mg QD vs.
 febuxostat 240 mg QD 0.78 (0.49, 1.24) 403 1 281 NA
 placebo 0.85 (0.56, 1.27) 479 3 318 0.0%
febuxostat 240 mg QD vs.
 placebo 1.04 (0.61, 1.78) 268 1 195 NA
pegloticase 8 mg 2 W vs.
 pegloticase 8 mg 4 W 11.55 (0.63, 212.19) 169 1 164 NA
 placebo 10.18 (0.48, 216.91) 127 1 125 NA
pegloticase 8 mg 4 W vs.
 placebo 0.78 (0.15, 4.20) 128 1 121 NA
  1. NA = not available.